Aspire Biopharma Holdings, Inc. (ASBP)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 2K | 4K | 28K |
| Gross Profit | 884.00 | -1K | 6K | |
| Operating Income | -800K | -1.1M | -1.8M | -1.6M |
| Net Income | -2.0M | -1.9M | -4.7M | -3.2M |
| Diluted EPS | $-48.00 | $-48.00 | $nan | $-20.57 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 6K |
| Gross Profit | 0.00 | 0.00 | 0.00 | -116.00 |
| Operating Income | -596K | -1.3M | -1.2M | -19.4M |
| Net Income | -597K | 4.5M | -1.3M | -24.5M |
| Diluted EPS | $-15.57 | $116.44 | $-34.17 | $-491.40 |